Pharmaceuticals in Spain

Date: September 26, 2016
Pages: 35
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PD227361E0CEN
Leaflet:

Download PDF Leaflet

Pharmaceuticals in Spain
SUMMARY

Pharmaceuticals in Spain industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY FINDINGS
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Spain
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Spain
  • Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Spain pharmaceuticals market with five year forecasts
SYNOPSIS

Essential resource for top-line data and analysis covering the Spain pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

REASONS TO BUY
  • What was the size of the Spain pharmaceuticals market by value in 2015?
  • What will be the size of the Spain pharmaceuticals market in 2020?
  • What factors are affecting the strength of competition in the Spain pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in Spain's pharmaceuticals market?
KEY HIGHLIGHTS

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2015 annual average exchange rates.

The Spanish pharmaceuticals market had total revenues of $16.1bn in 2015, representing a compound annual growth rate (CAGR) of 0.7% between 2011 and 2015.

Spain's main factor disrupting pharma growth is its continued economic uncertainty. This has reduced public healthcare budgets and simultaneously restricted the spending power of consumers in the private sector as well.

The performance of the market is forecast to accelerate, with an anticipated CAGR of 2.2% for the five-year period 2015 - 2020, which is expected to drive the market to a value of $17.9bn by the end of 2020.
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Almirall S.A.
AstraZeneca PLC
GlaxoSmithKline Plc
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: Spain pharmaceuticals market value: $ billion, 2011-15
Table 2: Spain pharmaceuticals market geography segmentation: $ billion, 2015
Table 3: Spain pharmaceuticals market share: % share, by value, 2015
Table 4: Spain pharmaceuticals market value forecast: $ billion, 2015-20
Table 5: Almirall S.A.: key facts
Table 6: Almirall S.A.: key financials ($)
Table 7: Almirall S.A.: key financials (€)
Table 8: Almirall S.A.: key financial ratios
Table 9: AstraZeneca PLC: key facts
Table 10: AstraZeneca PLC: key financials ($)
Table 11: AstraZeneca PLC: key financial ratios
Table 12: GlaxoSmithKline Plc: key facts
Table 13: GlaxoSmithKline Plc: key financials ($)
Table 14: GlaxoSmithKline Plc: key financials (£)
Table 15: GlaxoSmithKline Plc: key financial ratios
Table 16: Spain size of population (million), 2011-15
Table 17: Spain gdp (constant 2005 prices, $ billion), 2011-15
Table 18: Spain gdp (current prices, $ billion), 2011-15
Table 19: Spain inflation, 2011-15
Table 20: Spain consumer price index (absolute), 2011-15
Table 21: Spain exchange rate, 2011-15

LIST OF FIGURES

Figure 1: Spain pharmaceuticals market value: $ billion, 2011-15
Figure 2: Spain pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 3: Spain pharmaceuticals market share: % share, by value, 2015
Figure 4: Spain pharmaceuticals market value forecast: $ billion, 2015-20
Figure 5: Forces driving competition in the pharmaceuticals market in Spain, 2015
Figure 6: Drivers of buyer power in the pharmaceuticals market in Spain, 2015
Figure 7: Drivers of supplier power in the pharmaceuticals market in Spain, 2015
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Spain, 2015
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Spain, 2015
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Spain, 2015
Figure 11: Almirall S.A.: revenues and profitability
Figure 12: AstraZeneca PLC: revenues and profitability
Figure 13: AstraZeneca PLC: assets and liabilities
Figure 14: GlaxoSmithKline Plc: revenues and profitability
Figure 15: GlaxoSmithKline Plc: assets and liabilities

COMPANIES MENTIONED

Almirall S.A.
AstraZeneca PLC
GlaxoSmithKline Plc
Skip to top


OTC Pharmaceuticals in Spain US$ 350.00 Sep, 2016 · 38 pages
The Pharmaceutical Market: Spain US$ 1,295.00 Jan, 2013 · 93 pages

Ask Your Question

Pharmaceuticals in Spain
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: